{
    "relation": [
        [
            "",
            "Olanzapine",
            "Risperidone",
            "Molindone"
        ],
        [
            "Description",
            "oral olanzapine 5-20mg per day for up to 52 weeks",
            "oral risperidone 0.5mg to 6mg daily for up to 52 weeks",
            "oral molindone from 10-140mg/daily for up to 52 weeks"
        ]
    ],
    "pageTitle": "Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00053703?sect=X025&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989507.42/warc/CC-MAIN-20150728002309-00284-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 884812193,
    "recordOffset": 884796607,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details From February 2002 to May 2006, youth were screened at four academic sites: University of North Carolina at Chapel Hill, McLean Hospital and Cambridge Health Alliance at Harvard Medical School, University of Washington, and Case Western Reserve University. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Risperidone Drug: Olanzapine (enrollment closed in this treatment) Drug: Molindone Interventions: Schizophrenia Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Olanzapine \u00a0 \u00a0 Risperidone \u00a0 \u00a0 Molindone \u00a0 STARTED \u00a0 \u00a0 35 \u00a0 \u00a0 41 \u00a0 \u00a0 40 \u00a0 COMPLETED \u00a0 \u00a0 17 \u00a0 \u00a0 28 \u00a0 \u00a0 25 \u00a0 NOT COMPLETED \u00a0 \u00a0 18 \u00a0 \u00a0 13 \u00a0 \u00a0 15 \u00a0 \u00a0 Baseline Characteristics \u00a0 Show Baseline Characteristics \u00a0 Outcome Measures",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}